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Abstract
Rheumatoid arthritis (RA) is a major cause of adult chronic inflammatory arthritis and a typical complex trait. Although
several genetic determinants have been identified, they account for only a part of the genetic susceptibility. We conducted
a genome-wide association study of RA in Japanese using 225,079 SNPs genotyped in 990 cases and 1,236 controls from
two independent collections (658 cases and 934 controls in collection1; 332 cases and 302 controls in collection2), followed
by replication studies in two additional collections (874 cases and 855 controls in collection3; 1,264 cases and 948 controls
in collection4). SNPs showing p,0.005 in the first two collections and p,10
24 by meta-analysis were further genotyped in
the latter two collections. A novel risk variant, rs2000811, in intron2 of the myelin basic protein (MBP) at chromosome 18q23
showed strong association with RA (p=2.7610
28, OR 1.23, 95% CI: 1.14–1.32). The transcription of MBP was significantly
elevated with the risk allele compared to the alternative allele (p,0.001). We also established by immunohistochemistry
that MBP was expressed in the synovial lining layer of RA patients, the main target of inflammation in the disease.
Circulating autoantibody against MBP derived from human brain was quantified by ELISA between patients with RA, other
connective tissue diseases and healthy controls. As a result, the titer of anti-MBP antibody was markedly higher in plasma of
RA patients compared to healthy controls (p,0.001) and patients with other connective tissue disorders (p,0.001). ELISA
experiment using citrullinated recombinant MBP revealed that a large fraction of anti-MBP antibody in RA patients
recognized citrullinated MBP. This is the first report of a genetic study in RA implicating MBP as a potential autoantigen and
its involvement in pathogenesis of the disease.
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Rheumatoid arthritis (RA) is the most common cause of adult
inflammatory arthritis, affecting 0.5–1% of the adult population
worldwide, and is associated with joint pain, dysfunction and
deformity. Both genetic and environmental risk factors have been
implicated in RA [1–2]. HLA-DRB1 is a major genetic component
of RA across ethnicities and is estimated to contribute to 30 to
50% of the total genetic risk [3]. However, the other risk loci
identified to date show ethnic-specific patterns of disease
association. Large-scale genetic analyses including genome-wide
association (GWA) studies have shown that more than 20 genes
such as PTPN22, TRAF1/C5, CD40, and TNFAIP3 are associated
with RA in populations of European descent [4–12]. A different
set of non-HLA genes, namely, PADI4, SLC22A4, FCRL3, CD244
and CCR6 were first reported for their association with RA using
Japanese DNA collections [13–17]. Among them, several genes
including CCR6, STAT4 and TNFAIP3 were later proven their
association beyond ethnicity [12,18–19]. On the other hand, some
other genes showed strong specificity to a certain ethnic group.
The association of the PTPN22 has been repeatedly reproduced by
subsequent genetic studies in Europeans [5,20–21]. However, no
evidence of strong disease risk in PTPN22 was shown in Japanese
in part due to a much lower frequency of the risk allele [22].
Similarly the association of PADI4 with RA, which has been
confirmed by multiple genetic studies in Japanese and Koreans
[23–24], is found to be much weaker in Europeans [25–26].
Moreover, the size of DNA collections used for GWA studies is
much larger in European populations than in Japanese, suggesting
the existence of unknown genetic factors in Japanese [12,17]. For
these reasons, we decided to conduct a new large-scale GWA study
of RA in Japanese. Independent collections of RA patients and
controls were enrolled from four clinical centers in our study. The
collections from two centers, totaling 990 cases and 1,241 controls,
were characterized with genome-wide SNP arrays, and the data
were analyzed to identify potential disease-associated loci. For
replication, SNPs at these loci were examined in the two
remaining collections, totaling 2,138 cases and 1,803 controls.
Results
Genome scan and validation studies
We accumulated data on 3,128 cases and 3,039 controls of four
independent RA collections (termed as collections 1,2,3 and 4,
Table S1). Collections 1 and 2 (totaling 990 cases and 1,236
controls) were used for GWA analysis and collections 3 and 4
(totaling 2,138 cases and 1,803 controls) were used as replication
samples. Quality control of the GWA genotyping results was
undertaken separately in cohorts 1 and 2 because of differences in
the SNP arrays used (see Methods, Table S2). For 225,079
markers that were common between the arrays and fulfilled our
inclusion criteria, we found no evidence of population stratification
between cases and controls (genomic control inflation factor
l=1.03, Figure S1). We undertook analysis of each collection
individually, and a meta-analyses to pool the results in the two
collections in the association analysis (see Methods for further
details). We report p-values from the meta-analysis unless
otherwise stated.
We found a strong association of disease risk with markers in the
HLA complex [27] (p=5.0610
231, Table S3). Although no other
chromosomal loci showed genome-wide significance, we detected
evidence of association signal in PADI4 (p=2.3610
25), as
previously reported in Japanese [13,23,27] (Table S3). The
association results of five reported genes in Japanese were shown
in Table S4. These results support the quality of our study
populations for genetic analysis. In addition, we identified 10 SNPs
in five additional chromosomal regions that met our statistical
criteria for testing in the replication collections (p,0.005 in both
collections 1 and 2, and p,10
24 in the meta-analysis). None of
them showed potential association with p-value being smaller than
10
25 in the other Japanese GWA study [17]. From each of these
regions, the SNP with the smallest p-value was selected for
examination in collections 3 and 4. One of these SNPs, rs2000811
(p=0.0036 in collection1; p=5.7610
24 in collection2;
p=1.2610
25 in the meta-analysis) located on chromosome
18q23, was significantly associated with RA in both replication
collections (p=0.023 in collection3; p=0.0041 in collection4, and
Table 1. Association of MBP locus with rheumatoid arthritis in the Japanese population.
Chr dbSNPID Gene Allele DNA Collection Genotype counts
Success
rate HWEp RAF** p-value OR mhp***
Ref.(A1)/Var.(A2) A1A1 A1A2 A2A2 (95%CI)
18q23 rs2000811 MBP C/T* 1 case 203 303 136 99.8 0.25 0.45 0.0036 1.25
control 344 442 148 100 0.76 0.4 (1.08–1.44)
2 case 95 152 79 99.7 0.24 0.48 5.7610
24 1.49
control 120 131 46 100 0.31 0.38 (1.19–1.87)
3 case 283 392 182 98.1 0.034 0.44 0.023 1.17
control 298 404 134 97.8 0.88 0.4 (1.02–1.34)
4 case 393 622 233 98.7 0.63 0.44 0.0041 1.19
control 341 451 141 98.4 0.68 0.39 (1.06–1.35)
3+4 case 676 1014 415 98.5 0.32 0.44 3.0610
24 1.18
control 639 855 275 98.1 0.69 0.4 (1.08–1.30)
pooled case 974 1469 630 98.9 0.078 0.44 4.0610
28 1.23 2.7610
28
control 1103 1428 469 98.9 0.85 0.39 (1.14–1.32)
*risk allele for the disease,
**risk allele frequency, and
***p-value in meta-analysis using Cochran-Mantel-Haenszel test.
doi:10.1371/journal.pone.0020457.t001
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24 in collections 3 and 4). When the four collections
were combined, the evidence of association at rs2000811 exceeded
genome-wide significance when evaluated either by meta-analysis
(p=2.7610
28; OR=1.23; 95%CI 1.14–1.32) or by pooling of the
genotype counts (p=4.0610
28; OR=1.23; 95%CI 1.14–1.32; see
Table 1). There was no difference in the effect size among the four
collections (p=0.28). To be more conservative, however, we have
calculated corrected p-values with Principle Component Analysis
(PCA), using subsets of case and control collections for which
individual genotypes were available (970 cases and 297 controls,
for details, see Materials and Methods). There was no difference in
p-values with and without the correction (p=6.5610
24 and
corrected p=6.5610
24). The four SNPs from the other regions
that were tested showed no evidence of association in collection3
for replication study (Table S5).
The disease associated marker rs2000811 is located in the second
intron of the MBP (myelin basic protein) gene at chromosome
18q23 within a 156-kb region that contains the MBP gene (NCBI
MapViewer,build36.3).Linkage disequilibrium (LD)wasevaluated
using genotyping results obtained in collections 1 and 2; rs2000811
did not show significant LD with other markers from the region
(r
2,0.14; Figure 1), or elsewhere in the genome. An imputation
analysis using the Japanese HapMap data identified a SNP,
rs9958028, which was 358-bp apart and in strong LD with
rs2000811 (r
2=0.96), as the second strongest association. However,
no other marker was in strong LD with these two markers (r
2=0.35
or smaller) (Figure S2). To determine if unidentified polymorphisms
within MBP were in LD with rs2000811, we performed a
sequencing of the exons and the promoter region of the MBP gene
in 84 Japanese population control DNAs (Method S1). We
identified 66 SNPs, 37 of which were not registered in dbSNP,
and three of which were deleterious polymorphisms (Tables S6 and
S7). Again, none of these polymorphisms was in strong LD with
rs2000811 (r
2=0.35 or smaller) (Figure S3). An imputation analysis
using the genotyping results obtained by sequencing did not
discover any other polymorphisms showing stronger association
signals (p.0.0070) than that of rs2000811. Taken together, these
data suggest that rs2000811 and/or one or more other as yet
unidentified non-coding polymorphisms within or near MBP are
responsible for the genetic association.
Figure 1. A schematic view of the association results and LD structure of the human MBP gene locus at chromosome 18q23. SNPs
located between rs470131 and rs2717096 are plotted in 2log10 scale according to their chromosomal positions and p-values calculated with
Cochran-Mantel-Haenszel test. Red circle indicates mhp-value of rs2000811 by meta-analysis using the combined results of collections 1 to 4. Relative
locations of the genes in the region are shown with their transcriptional orientations by arrows. LD blocks were generated using the genome scan
results.
doi:10.1371/journal.pone.0020457.g001
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Quantitative RT-PCR experiments showed only very low levels
of MBP expression in RNA from Epstein-Barr virus (EBV)-
transformed human B-lymphoblastoid cell lines, and we could
detect no discernable correlation of MBP transcript levels with
different risk genotypes (p=0.36, Figure S4). By a similar reason,
in-silico expression analysis using GEO database did not return
clear association [28]. However, when we performed allele-specific
quantitative RT-PCR [16] using genomic DNA and cDNA of
these cell lines, we observed elevated allele-specific transcription
associated with the risk allele (p,0.001, Figure 2, for detailed
procedure, see Materials and Methods). This suggests that
rs2000811, and/or other variants in linkage disequilibrium with
this marker, impact the quantitative pattern of MBP transcription.
However, bioinformatics analysis identified no known cis-acting
elements covering rs2000811 that could be inferred to have
functional effects (Method S2). In addition, the alignment of the 4-
kb region ranging between 2-kb centromeric and 2-kb telomeric to
rs2000811 revealed that this segment has very low interspecies
conservation among placental mammals.
Expression of the MBP protein in synovial tissues
Next we investigated the expression of the MBP protein in
synovial tissue, as this is the main target of inflammation in RA.
Microscopic observation revealed that MBP was highly expressed
along the lining layer of synovial tissues in 20 out of 23 RA patients
tested, while the expression of MBP was observed in only one out
of five controls (p=0.0017), and then generally at a weaker level
(Figure 3A, B). In synovial tissue from RA patients, the detected
MBP expression was weaker in synovial lining layer adjacent to the
follicules of infiltrated lymphocytes (Figure 3C). In synoviocytes,
the expression of MBP was mainly observed in the plasma
membrane (Figure 3D).
Quantification of antibodies to MBP in RA patients
AntibodiestoMBParethemajorcomponent ofautoantibodiesin
multiple sclerosis,a human autoimmunitywitha neurodegenerative
phenotype [29]. To assess a possible association of circulating
antibodiestoMBPwith RA,we quantifiedtheseinplasmafrom 323
RA cases, 131 healthy controls and 162 patients with other
connective tissue diseases (disease controls) by Enzyme-linked
immunosorbent assay (ELISA) with MBP purified from human
brain as antigen. The average levels of anti-MBP antibody in
plasma of RA patients were much higher than those of healthy
controls and patients with seven other connective tissue diseases
(p,0.001; Figure 4A). Specificity in detection of anti-MBP antibody
in ELISA experiments was confirmed by immunoblotting using
plasma of a subset of RA patients and controls (Figure S5, Method
S3). We also confirmed that the enhancement of ELISA signals by
non-specific binding of IgG- and IgM-RF in patients’ sera was
negligible (for details, see Method S4 and Figure S6).
Amino acid analysis of the MBP protein derived from human
brain showed that approximately 21% (citrulline/arginine=6.0/
23.1) of the arginine residues in MBP was citrullinated in human
brain under physiological conditions (Method S5). It is possible
that anti-MBP antibody recognizes and binds to citrullinated MBP
protein. We then performed ELISA using recombinant MBP
protein and compared the antibody titers with those of human
brain-derived MBP. We could not observe correlation between the
two results (r=20.19, Figure 4B). However, when we used
recombinant MBP protein artificially citrullinated in-vitro, the
ELISA results showed strong correlation in titers of the
autoantibody (r=0.88, Figure 4C). From these results, we
concluded that higher levels of anti-MBP antibody in RA patients
than in healthy controls and in patients with other connective
tissue diseases was attributed to autoantibodies binding to
citrullinated MBP.
Discussion
We conducted a large-scale GWA-based genetic study of RA in
the Japanese population. A genome scan of 225,079 SNPs in two
Figure 2. Allelic difference in MBP transcription using allele
specific quantitative RT-PCR. The amount of MBP primary
transcripts transcribed from chromosomes carrying rs2000811 risk (T)
and alternative (C) alleles was compared in each cell line, and the ratio
(T/C) was plotted. Genomic DNA was used as a control for equimoler
biallelic representation. Experiments were done twice independently.
doi:10.1371/journal.pone.0020457.g002
Figure 3. Immunohistochemistry of the MBP protein in human
synovial tissues stained by monoclonal anti-MBP antibody.
Synovial tissue of RA patients, in particular, along the synovial lining
layer strongly expressed MBP (A), whereas that of non-inflammatory
osteoarthritis patients was much weaker (B). The expression of MBP in
the synovial lining layer was weaker near follicules of infiltrated
lymphocytes (C). Localized expression of MBP was observed at the
plasma membrane of synoviocytes (D).
doi:10.1371/journal.pone.0020457.g003
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additional collections led to identification of a novel risk variant,
rs2000811 (p=2.7 610
28, OR 1.23, 95% CI: 1.14–1.32), in the
second intron of the MBP gene at chromosome 18q23. This is the
second largest genome-wide association study to date in the
Japanese population, and the first to have identified chromosome
18q23 as a potential susceptibility locus for RA. 18q23 was not
reported as a candidate genetic locus in recent GWA study of RA
in Japanese [17]. As summarized in Table S4, we confirmed in
the current study the association of three out of seven genes
reported to date whereas there was no evidence of association for
the other four genes. A comprehensive genetic study by a meta-
analysis using the results of different genome scans followed by
the validation study with a large number of patients and controls
will clarify relative contribution of each genetic locus to RA in the
Japanese population. There are no GWA studies to date that
indicate chromosome 18q23 as a potential genetic locus related to
the susceptibility to RA in European populations [5–12]. By
taking into account the detection power of the meta-analysis by
Stahl et al., it is natural to consider that the association of MBP
with RA is limited to Japanese (and possibly other Asian
populations).
The disease-associated marker rs2000811 is isolated in an 18-kb
segment of the intron, and does not show evidence of significant
LD with known markers in the region or neighboring genomic
regions (Figure 1). The LD structure of the human MBP locus was
very similar between Europeans and Japanese, and there was no
clear LD block in the region encompassing rs2000811 in both
populations (Figure S2). Sequencing of the DNAs of 84 healthy
controls failed to identify other polymorphisms that were in strong
LD with rs2000811 in the exons or the promoter region of the
MBP gene. While bioinformatics analysis failed to identify any cis-
acting elements encompassing rs2000811, allele-specific expression
analysis demonstrated the elevated transcription level of MBP with
the risk allele. This raises the possibility that cis-acting regulatory
elements that encompass unknown genetic variations in strong LD
with rs2000811.
A strong expression of the MBP protein was observed in
synoviocytes of RA patients while expression was weaker in those
of non-inflammatory controls. The fact that the expression of
MBP was strongest in the synovial lining layer suggests the role of
anti-MBP antibody as a trigger of inflammatory reactions
through attacking synoviocytes. Although a study investigating
citrullinated proteins in synoviums did not clearly identify MBP
[30], MBP is possibly one of the unidentified subset of the
citrullinated proteins. MBP expression was weaker in synovio-
cytes adjacent to the follicules of infiltrated lymphocyte. It would
be of interest to examine whether MBP in synovium is
Figure 4. Quantification of circulating antibodies against MBP protein. A. Each boxplot indicates distribution of anti-MBP antibody titers in
healthy controls, in RA patients, and in other connective tissue diseases (CTDs) (for detailed composition of the disease patients, see materials and
methods). Results were representative of the two independent experiments. *** indicates statistical p-value smaller than 0.001. B. Correlation of
autoantibody levels between human brain-derived MBP and recombinant MBP (rMBP). C. Correlation of autoantibody levels between human brain-
derived MBP and citrullinated rMBP. Sixty RA patients who were positive for anti-MBP antibody were used for the analysis. In each figure, antibody
titers were shown as arbitrary unit (AU).
doi:10.1371/journal.pone.0020457.g004
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activity, in particular, at different stages of proliferative synovitis
but data for such an investigation are not available in our study.
In the absence of a quantitative assay of expression in
synoviocytes, it was not possible to discern a correlation between
the levels of MBP expression with the risk genotype in our
experiments.
MBP is a well-known target autoantigen in multiple sclerosis
(MS), a human neurodegenerative disease with an active
destruction of myelin sheath [29]. The MBP protein has six
different isoforms of which isoforms 1, 2, 3 and 4 with shorter
open reading frames are expressed preferentially in the central
nervous system (CNS). Isoforms 7 and 8 with higher molecular
weights (also called Golli-MBP) are known to be expressed
relatively ubiquitously including cells of the hematopoietic lineage
[31]. The fact that RA patients rarely present CNS symptoms
may suggest the involvement of Golli-MBP protein in the
generation of anti-MBP antibody and expression in the
synovium. An immunological study using relatively small
numbers of plasma samples showed that anti-MBP antibody is
present in 60% (or six out of ten) of RA patients [32]. To our
knowledge, however, there is no study which quantitatively
characterized anti-MBP antibody in RA patients as well as in
patients of other connective tissue diseases and in healthy
controls. On the other hand, ACPA which recognizes citrulli-
nated proteins by peptidylarginine deiminase is considered as a
specific and predictive marker for RA [13,33–34]. Indeed, several
studies showed the existence of antibodies to citrullinated MBP in
RA patients [35–36]. However, the role of MBP and anti-MBP
antibody in the pathogenesis of RA is yet to be elucidated. In the
current study, we found that a part of brain-derived MBP was
citrullinated in physiological conditions and that higher levels of
anti-MBP antibody in RA patients can be attributed to MBP
citrullination, although anti-MBP antibody is not in complete
cross-reactivity with ACPA. We examined whether or not
rs2000811 was predominantly associated with patients who were
positive for ACPA. However, there was no statistical difference in
allele frequency of rs2000811 between patients with and without
ACPA (p=0.40, data not shown).
We observed no correlation between the levels of anti-MBP
antibody and genotypes at the risk locus. The repertoire of
autoantibody is likely to depend on numerous factors such as the
immunogenicity and extent of citrullination of the MBP protein.
Also, a series of immunological reactions including antigen
presentation in thymus and peripheral organs, activation of
dendritic cells, T- and B-lymphocytes, and balance of Th1/Th2
and effector/regulatory T-lymphocytes affect antibody produc-
tion. A possible explanation for the lack of correlation is that the
disease-associated genotypes affect these factors in a way that
impacts risk without directly influencing the quantitative values of
anti-MBP antibody, which we find to be highly variable between
RA patients that we have studied. Therefore, it will be of interest
to compare the expression levels of MBP transcripts and MBP
epitopes in synovial tissue, and between different genotypes and
disease activity.
Taken together, this is the first genetic study which identified
MBP, an autoantigen gene, to be associated with RA in Japanese.
Transcription of MBP was increased with the risk allele of the
associated SNP, rs2000811. Strong expression of the MBP protein
was observed in the synovial tissues of the patients. Furthermore,
significant increase of circulating autoantibodies against MBP
protein was demonstrated in RA patients as compared to those
with other connective tissue diseases, implicating its role as a
disease-associated biomaker.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all the participants
at the institute of sample collection after being approved for
genetic studies by the local ethical committee, namely, Kyoto
University Graduate School and Faculty of Medicine, Ethics
Committee, The Ethic Committee, Sagamihara National Hospi-
tal, NHO, Dohgo Spa Hospital Ethical Committee, University of
Tokyo Medical Research Center Ethics Committee, Tokyo
Women’s Medical University Genome Ethics Committee, Ethics
Committee of Tokyo Women’s Medical University and Aichi
Cancer Center Ethical Committee for human genome research.
Study subjects
RA collections 1 to 4 consisted of 658 affected individuals and 934
controls, 332 and 302, 874 and 855, and 1,264 and 948, respectively
(summarized in Table S1). The case subjects of collections 1, 2 and 3
wererecruited at therheumatologydepartmentsofKyotoUniversity
Hospital, Dohgo Spa Hospital, Sagamihara National Hospital, and
Tokyo University Hospital, and those for collection4 were from
Tokyo Women’s Medical University. All cases fulfilled the revised
criteria (1987) of the American College of Rheumatology (ACR) for
rheumatoid arthritis [37]. Genotype count data of the Japanese
Single Nucleotide Polymorphism (JSNP) database [38] were used as
controls for collection1. The control subjects for collection2 were
from the Department of Ophthalmology and Visual Science at
Kyoto University Hospital [39]. DNA samples of healthy Japanese
volunteers in Pharma SNP Consortium [40] and in Aichi Cancer
CenterHospitalandResearchInstitute[41]wereusedforcollections
3 and 4, respectively. Plasma of 323 RA patients and 162 patients of
other connective tissue diseases (38 of SLE, 25 each of Sjo ¨gren’s
syndrome and systemic sclerosis, 20 each of Behc ¸et’s disease and
mixed connective tissue disease, 19 of polymyositis/dermatomyositis
and 15ofvasculitis) were obtainedat KyotoUniversityHospital,and
those of 131 healthy controls were from Dohgo Spa Hospital.
Genome-wide association analysis
Genome scan for collections 1 and 2 was performed using
Infinium Technology (Illumina Inc., San Diego, CA). Case
subjects of collection1 were genotyped with Human-Hap300
(version 1.0, 302,627 SNPs) or Human CNV370-Duo (version 1.0,
332,270 SNPs). For collection2, case and control subjects were
genotyped on Human610-Quad (version 1.0, 577,348 SNPs), and
HumanHap550 (version 3.0, 547,163 SNPs), respectively. Valida-
tion studies using collections 3 and 4 were performed using
Taqman technology (Applied Biosystems Inc., Foster City, CA)
according to the manufacturer’s specifications.
Quality control and statistical tests for case-control
association
277,420 SNPs that were common among the four arrays
described above were chosen for association study. Publicly
available genotype counts from the JSNP project were used as
control collection1. For this collection, detailed information such
as individual genotypes and cluster plots are not disclosed. DNA
samples with a call rate smaller than 0.90 (three in collection1
cases), showing high degree of kinship (PI_HAT.0.10 by PLINK
[42], eleven in collection1 cases, one in collection2 cases, and four
in collection2 controls) and with evidence of possible contamina-
tion (one in collection2 controls) were removed from statistical
analyses. PCA was performed using the genome scan results of the
remaining 644 cases of collection1, in addition to 331 cases and
297 controls of collection2. At this stage, five DNA samples (one in
Myelin Basic Protein, Risk of Rheumatoid Arthritis
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into the Japanese cluster were removed. Regarding the SNP
markers, a total of 225,079 SNPs with call rate greater than 0.95
for both cases and controls and minor allele frequency greater
than 0.05 either in case or in control of each collection were used
for analysis. The p-value for rs2000811 corrected by PCA was
calculated using the remaining 970 cases and 297 controls and
compared with the p-value without correction.
The case-control association was examined independently for
collections 1 and 2 with Cochran-Armitage trend test, followed by
meta-analysis with Cochran-Mantel-Haenszel (CMH) test by
combining the two collections. Population stratification in collec-
tions 1 and 2 was examined and corrected with Genomic Control
[43]. The SNPs that showed p,0.005 in both collections and meta-
analysis p-value smaller than 10
24 were selected as candidates for
further evaluation. Among multiple SNPs in the same region that
fulfilled the above criteria, the SNP with the smallest p-value in the
meta-analysis was chosen for validation with collections 3 and 4. To
be more specific, among the four SNPs in the PLEKHK1 region on
chromosome 10q21, namely rs3910172 (p=4.4610
25), rs6479805
(p=5.4610
25), rs10733769 (p=5.8610
25), and rs4147233
(p=6.6610
25), rs3910172 was selected for the replication study.
Likewise, in the region of chromosome 10p14, rs2026628
(p=1.6610
25) was chosen over rs11253857 (p=5.3610
25), and
rs687848 (p=5.1610
25) was chosen over rs587404 (p=7.1610
25)
in the MACF1 region on chromosome 1p31–32. SNPs in the HLA
and PADI4 loci were not included in validation studies. Haploview
version 4.1 software [44] was used for LD evaluation, and
MapViewer (build 36.3) [45] was used to identify the location and
structure of the genes in the region.
Quantification of allelic difference in gene expression in
MBP transcription
Allele specific gene expression analysis was performed as
previously described [16]. Briefly, human B-lymphoblastoid cell
lines transformed by EBV were obtained from the Health Science
Research Resources Bank of Japan (Osaka). Genomic DNA and
total RNA were extracted by standard procedures from 22 cell
lines heterozygous for rs2000811 alleles. The ratio of MBP
primary transcripts (hnRNA) was quantified between the risk and
wild-type alleles by TaqMan assay with SNP genotyping probes.
Genomic DNA of a cell line homozygous for the wild-type allele
(C) were mixed with DNA homozygous for the risk allele (T) at
eight different molar ratios (2:1, 3:2, 1:1, 2:3, 1:2, 1:3, 1:4, 1:6) to
draw a standard curve for the evaluation of RNA quantity.
Immunohistochemistry
Synovial tissue specimens of 23 RA patients and five non-
inflammatory controls were obtained from Department of Diag-
nostic Pathology and Department of Orthopaedic Surgery in Kyoto
University Hospital. Paraffin-embedded tissues were prepared in a
standard method and sectioned at a thickness of 3 mm. The section
was mounted on a glass slide coated with 2% 3-aminopropyl
triethoxy silane (Tokyo Kasei, Tokyo, Japan). Immunohistochem-
ical staining of MBP was performed by using the standard avidin-
biotin-peroxidase complex (ABC) method, as previously described
[46]. The sections were incubated overnight at 4uC with an affinity-
purified murine anti-human MBP monoclonal antibody (Leica
Microsystems, Wetzlar, Germany) diluted at 1:100 in PBS. The
sections were then incubated with biotinylated horse anti-mouse
IgG antibody (Vector Lab, Burlingame, CA) for 40 minutes,
followed by incubation with peroxidase-conjugated streptavidin
(Vector Lab, Burlingame, CA) at room temperature for 50 minutes.
The coloring reaction was performed with 0.3 mg/ml diamino-
benzidine and 0.003% H2O2 in 50 mM Tris-HCl (pH 7.6). Each
section was counterstained with haematoxylin. Evaluation of MBP
expression was performed by a blind test by two rheumatologists as
well as a pathologist, and statistical significance in positivity was
calculated with Fisher’s exact test.
Enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (Nalge Nunc International K.K., Tokyo,
Japan) were coated with 50 ml of MBP protein at 5 mg/ml
extracted from human brain (Sigma, St. Louis, MO) or with
recombinant human MBP (Genscript, Piscataway, NJ.) in 50 mM
bicarbonate buffer (pH 9.6) and incubated at 4uC overnight.
Citrullination of recombinant human MBP was done in-vitro by
rabbit skeletal PAD (Sigma, St. Louis, MO) for 3 hours as
previously described [47]. After wells were washed and coated
with phosphate-buffered-saline (PBS) containing 2% bovine serum
albumin (BSA), 50 ml of plasma samples diluted to 1:150 with 2%
BSA in PBS containing 5 U/ml heparin (Mochida Pharmaceutical
Co., Ltd. Tokyo, Japan) were added and incubated at room
temperature for 2 hours. 50 ml each of purified goat anti-human
IgG polyclonal antibody conjugated to alkaline phosphate
(Millipore. Billerica, MA) diluted to 1:2000 was added and
incubated at room temperature for 1.5 hours. 50 ml of BCIP/NBT
substrate (Sigma, St. Louis, MO) in 2 mM MgCl2 was then added
and incubated for 45 minutes in the dark. The optical density
(OD) value at 405 nm was measured by a SpectraMax Plus
384
Microplate Reader (Molecular Devices, Sunnyvale, CA). A
standard curve was generated by serial dilution (1:50, 1:150,
1:500, 1:1500 and 1:5000) of a plasma sample with a high titer of
anti-MBP antibody. The titer of diluted standard sample in 1:50
was set as 100 U for human brain-derived MBP. All samples were
examined in duplicate except for negative control in which plasma
was replaced by PBS with 2% BSA and was measured in
quadruplicate. The specificity of ELISA results was confirmed by
standard immunoblotting analysis using sera of 10 each of RA
patients and controls.
Statistical analysis of ELISA results
The titer of anti-MBP antibody between RA or its subgroups
and controls was compared with Wilcoxon rank-sum test. The
correlation between the titers of autoantibody was estimated with
Pearson’s correlation coefficient in logarithm scale. These statistics
were performed in the R statistical system (http://www.R-project.
org) and SPSS(ver18).
Supporting Information
Figure S1 QQ plot to show the observed and expected p-
values of the combined genome scan results. Vertical and
horizontal axes indicate observed and expected p-values, respec-
tively (A) and in logarithmic scale (B). The analysis using genomic
control method showed no significant effect of population
stratification (lGC=1.03) between the case and control groups.
(TIF)
Figure S2 Imputation analysis and LD structure of the
human MBP locus. Imputation was performed using the case
genotypes of collections 1 and 2 and control genotypes of
collection2. Individual genotypes of control population of
collection1 (JSNP) were not available. Determination of LD
structure was performed by using the GWAS results in this study
and the HapMap results of Japanese and Caucasians (Hap JPT
and Hap CEU, respectively).
(TIF)
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the MBP gene. LD plot was generated with Haploview using
polymorphisms with reference allele frequencies between 0.05 and
0.95.
(TIF)
Figure S4 Quantification of allelic difference in MBP
transcription. Human B-lymphoblastoid cell lines transformed
by EBV were obtained from the Health Science Research
Resources Bank of Japan (Osaka, Japan). Total RNA was
extracted by standard procedures from the cell lines that were
either homozygous for the wild-type allele (50 cell lines),
heterozygous (50 cell lines) or homozygous for the risk allele (49
cell lines) of rs2000811. The amount of MBP cDNA in each cell
line was measured and normalized to that of b-glucronidase using
Taqman Gene Expression Assay (for MBP; Hs00921943-m1, for
b-glucronidase; Hs99999908_m1, Applied Biosystems Inc., Foster
City, CA) in GeneAmp 7500 Sequence Detection System. The
comparative DDCT method and Jonckheere-Terpstra test were
used for the analysis.
(TIF)
Figure S5 Immunoblotting of anti-MBP antibody. Im-
munoblotting analysis was performed to confirm specific binding
of circulating anti-MBP antibody. Lane 1, 2 to 6 and 7 were
incubated with control plasma, plasma of patients, and rabbit
polyclonal anti-human MBP antibody, respectively. The intensity
was variable between RA patients whereas no signal was obtained
in controls. Similar results were obtained using plasma of the other
five RA patients and nine controls.
(TIF)
Figure S6 Comparison of circulating anti-MBP anti-
body and IgG-RF. We investigated whether the presence of
RF in sera enhances the signal in ELISA through binding
of IgG-RF to the constant region of anti-MBP antibody or
through non-specific binding of IgM-RF to secondary antibody
used in the experiments. Initially, correlation between IgG-RF
and anti-MBP antibody titers was assessed to examine whether
IgG-RF had any influence on anti-MBP antibody titers. 114
patients with RA and 13 other connective tissue disease
patients for whom IgG-RF measurement was available were
enrolled in this evaluation. As a result, no correlation was
observed between the titers of anti-MBP antibody and IgG-RF
(Spearman’s rank-sum coefficient being 0.145 with p-value of
0.103). Subsequently, ELISA experiments using human IgM or
IgG as target antigens were undertaken. Non-specific binding
of secondary antibodies to human IgM compared to IgG was less
than 1%.
(TIF)
Table S1 Summary of the study populations used for
the association analysis. Abbreviations were as follows;
ACPA: antibodies to citrullinated peptide antigens, RF: rheuma-
toid factor, SD: standard deviation, N/A, not available.
(DOC)
Table S2 Summary of quality control for genome scan
results.
(DOC)
Table S3 Association of HLA and PADI4 loci with
rheumatoid arthritis in the Japanese population. *risk
allele for the disease, **risk allele frequency, and ***p-value in
meta-analysis using Cochran-Mantel-Haenszel test.
(DOC)
Table S4 Association of previously reported non-HLA
genes in the current study. *p-value in meta-analysis using
Cochran-Mantel-Haenszel test.
(DOC)
Table S5 Replication results of the four regions. The
order of SNPs is in accordance with mhp-value. Chromosome and
dbSNPIDrefertoNCBIbuild 36.3.P-valuesarecalculated using the
Cochran-Armitage trend test. *risk allele for the disease, **risk allele
frequency, and ***OR, odds ratio with 95% confidence interval.
***p-value in meta-analysis using Cochran-Mantel-Haenszel test.
(DOC)
Table S6 Oligonucleotide primers used for sequencing
of the exons and the promoter region of the MBP gene.
(DOC)
Table S7 The list of genetic polymorphisms discovered
by sequencing the exons and the promoter region of the
MBP gene. *Positions of polymorphisms are according to NCBI
Refseq Build 36.3. Polymorphisms are located between position 1
and position 2.
(DOC)
Method S1 Sequencing of the exons and the promoter
region of the MBP gene.
(DOC)
Method S2 Bioinformatics analysis.
(DOC)
Method S3 Immunoblotting of anti-MBP antibody.
(DOC)
Method S4 Evaluation of non-specific binding of sec-
ondary antibodies.
(DOC)
Method S5 Amino acid analysis.
(DOC)
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